表紙
市場調查報告書

高胰島素血症:開發中產品分析

Hyperinsulinemia - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 410991
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
高胰島素血症:開發中產品分析 Hyperinsulinemia - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 73 Pages
簡介

高胰島素血症,是相對於血液中的葡萄糖值,在血中有過剩的胰島素循環的狀態。胰島素抗性是高胰島素血症的根本原因。症狀有體重的增加,不安感,疲勞,反復的空腹感等。危險因素有高三酸甘油酯值,高尿酸,體重的增加,第二型糖尿病,高血壓等。使用胰島素分泌抑制劑作為治療,以及減肥、運動,其他生活方式的變更等。

本報告提供高胰島素血症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的新聞和發表開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等。

簡介

  • 調查範圍

高胰島素血症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

在大學/研究機關研究中的產品

開發治療藥的企業

  • Eiger BioPharmaceuticals Inc
  • Heptares Therapeutics Ltd
  • Seneb BioSciences Inc
  • XOMA Corp

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • exendin-(9-39)
  • 低血糖症、先天性高胰島素血症用GLP-1受體拮抗劑
  • SNB-2401
  • XOMA-358

暫停中的計劃

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11774IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Pipeline Review, H2 2019, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape.

Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise and other lifestyle changes.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperinsulinemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperinsulinemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Hyperinsulinemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperinsulinemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperinsulinemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperinsulinemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperinsulinemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperinsulinemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperinsulinemia - Overview
    • Hyperinsulinemia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hyperinsulinemia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hyperinsulinemia - Companies Involved in Therapeutics Development
    • AmideBio LLC
    • Crinetics Pharmaceuticals Inc
    • Eiger BioPharmaceuticals Inc
    • Hanmi Pharmaceuticals Co Ltd
    • PegBio Co Ltd
    • Rezolute Inc
    • Seneb BioSciences Inc
    • Sosei Heptares
    • XERIS Pharmaceuticals Inc
    • Zealand Pharma AS
  • Hyperinsulinemia - Drug Profiles
  • Hyperinsulinemia - Dormant Projects
  • Hyperinsulinemia - Discontinued Products
  • Hyperinsulinemia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hyperinsulinemia, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Hyperinsulinemia - Pipeline by AmideBio LLC, H2 2019
  • Hyperinsulinemia - Pipeline by Crinetics Pharmaceuticals Inc, H2 2019
  • Hyperinsulinemia - Pipeline by Eiger BioPharmaceuticals Inc, H2 2019
  • Hyperinsulinemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019
  • Hyperinsulinemia - Pipeline by PegBio Co Ltd, H2 2019
  • Hyperinsulinemia - Pipeline by Rezolute Inc, H2 2019
  • Hyperinsulinemia - Pipeline by Seneb BioSciences Inc, H2 2019
  • Hyperinsulinemia - Pipeline by Sosei Heptares, H2 2019
  • Hyperinsulinemia - Pipeline by XERIS Pharmaceuticals Inc, H2 2019
  • Hyperinsulinemia - Pipeline by Zealand Pharma AS, H2 2019
  • Hyperinsulinemia - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Hyperinsulinemia, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019